Specialty Area
Spotlight
Topics
Institute for Value-Based Medicine
About AJMC
Podcasts
CE
Subscribe
- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Key Differences Among ALK Inhibitors
Panelists discuss how currently available ALK inhibitors compare in terms of efficacy, durability of response, and central nervous system (CNS) penetration for metastatic non–small cell lung cancer treatment.
EP: 1.The Evolution of ALK+ NSCLC Care
EP: 2.Lorlatinib in Focus: Survival, Brain Metastases, and Beyond
EP: 3.Choosing Wisely: Insights from an MAIC and eXalt3
EP: 4.Applying Trial Data to Real-World Practice in ALK+ NSCLC
Now Viewing
EP: 5.Key Differences Among ALK Inhibitors
EP: 6.Navigating ALK Inhibitor Toxicities
EP: 7.Lorlatinib’s Unique Challenges: Managing Cognitive and Metabolic AEs
EP: 8.Long-Term Success: Educating and Supporting Patients on ALK Inhibitors
EP: 9.Equitable Access to Molecular Testing and Treatment Prioritization
EP: 10.Next Steps: Post-Frontline Therapies and Resistance in ALK+ NSCLC
EP: 11.Education and Support After Progression ALK Inhibitors
EP: 12.Looking Ahead: The Next Frontier in ALK+ NSCLC Therapy
ALK Inhibitor Comparison and CNS Penetration
Key Themes:
- Overview of currently available ALK inhibitors in the metastatic setting
- Comparative analysis of efficacy and durability of response
- Differences in CNS penetration among ALK inhibitors
Notable Insights:
- Dr Lovly provided a comprehensive overview of available ALK inhibitors and their comparative efficacy
Dr Dietrich highlighted clinically relevant differences in CNS penetration and their influence on therapy selection
Related Videos
Related Content
